Pimicotinib is an experimental drug that was tested in the international MANEUVER trial for the treatment of tenosynovial giant cell tumor (TGCT), a rare disease affecting tendons and joints.[1][5] In a phase 3 study, pimicotinib achieved an objective response rate of 54% at week 25 of treatment, while placebo achieved only 3.2% (p<0.0001).[1][5] The study included 94 patients from China, Europe and North America who were ineligible for or did not undergo surgical treatment.[1] In addition to the primary endpoint, pimicotinib demonstrated statistically significant improvements in all five key secondary endpoints, including reductions in pain (-2.32 point change vs. +0.23 for placebo) and joint stiffness (-3.00 point change vs. -0.57 for placebo).[1][5] At longer follow-up with a median of 14.3 months, the objective response rate increased to 76.2%.[6] The drug was well tolerated with a low incidence of discontinuation and dose reduction.[1] An application for approval of the drug is under review in China, and further applications are planned in the US and other countries.[6]